ClinicalTrials.gg
CompletedNCT00640432Updated Feb 2, 2021

Safety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain

A Phase 4 interventional study of Diclofenac and Celecoxib in Low Back Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 9 sites in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies in Low Back Pain with a site in Brazil — 10 open to participants now, 12 under way, none of them phase 3. Low Back Pain · Brazil.

Enrollment
8th of 122
244 · median 66
Started
2003
with 1 other
Phase 4
4 of 125
none open now
Registered
1st of 125
by date

Among the 125 studies in Low Back Pain with a site in Brazil, this one is the 8th largest by enrollment of the 122 interventional ones that give a count, is one of 2 that started in 2003, is one of 4 in phase 4, and was the 1st registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

10 of the 125 studies in Low Back Pain with a site in Brazil are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Low Back Pain with a site in Brazil, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of celecoxib versus sodium diclofenac in subjects with acute low back pain

03

Conditions studied

  • Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 65 years
  • Acute low back pain that falls into 1st or 2nd class of 'Quebec Task Force' classification of moderate to severe intensity (>50 mm in the VAS)
  • Acute low back pain onset \<72 hours prior to study inclusion and >6 weeks after the last acute low back pain episode

Exclusion criteria

Exclusion criteria:

  • Scoliosis or known history of inflammatory arthritis, chronic pain, , Paget's disease, or any other disease that cause pain
  • Low back pain from major trauma or visceral disorder
  • Esophageal ulcers, gastric or duodenal ulcers or bleeding within 30 days prior to being administered study drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
244 participants (actual)

Study arms

  • Active comparator
    A

    Drug: Diclofenac

  • Experimental
    B

    Drug: Celecoxib

Interventions

  • 75 mg oral capsule twice daily for 7 days

  • 400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days

06

What researchers measure

Primary outcomes

  1. Change from baseline in patient-rated visual analogue scale (VAS) pain intensity assessment

    Time frame: Day 3

Secondary outcomes

  1. Subject's quality of life, as measured by the SF-36 Health Survey

    Time frame: Day 7

  2. Physical examination

    Time frame: Days 3 and 7

  3. Pain relief score

    Time frame: Days 3 and 7

  4. Vital signs

    Time frame: Days 3 and 7

  5. Adverse events

    Time frame: Days 3 and 7

  6. Change from baseline in VAS pain intensity assessment

    Time frame: Day 7

  7. Categorical pain intensity score

    Time frame: Days 3 and 7

  8. Subject's global assessment score

    Time frame: Days 3 and 7

  9. Subject's functional ability, as measured by the "Roland Morris" Questionnaire about low back pain and disability

    Time frame: Day 7

07

Study locations

9 sites
  • Pfizer Investigational Site
    Salvador, BA 40420-000, Brazil
  • Pfizer Investigational Site
    Goiânia, GO 74043-110, Brazil
  • Pfizer Investigational Site
    Goiânia, GO 74075-020, Brazil
  • Pfizer Investigational Site
    Goiânia, GO 74605-050, Brazil
  • Pfizer Investigational Site
    Londrina, PR 86010-010, Brazil
  • Pfizer Investigational Site
    Rio de Janeiro, RJ 21215-020, Brazil
  • Pfizer Investigational Site
    Rio de Janeiro, RJ 21941-590, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 04039-004, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 08270-070, Brazil
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2008
First posted
Mar 21, 2008
Start
Oct 2003
CompletionActual
Oct 2004
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00640432
Responsible party
Sponsor
First posted
Mar 21, 2008
Start date
Oct 2003
Completion
Oct 2004
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion